Annegret de Baey-Diepolder
Private Equity Investor bei Seventure Partners SA
Profil
Dr. Annegret de Baey-Diepolder, MD, joined Seventure as a Venture Partner in April 2017.
Annegret is based in Munich, Germany and focuses mainly on Life sciences opportunities in DACH countries.
Since October 2011, she was independent consultant and interim manager in the biotech industry for 6 years, including co-founding & CEO of Rigontec GmbH, and CEO of ImmunOligo.
Previously, she worked for 10 years in venture capital mainly at TVM Capital in Munich and at GIMV NV in Munich/Antwerp.
She started her career in 1998 as senior research group leader developing therapeutic vaccines at Micromet AG, now Amgen.
Annegret holds a MD in human genetics from Ludwig-Maximilians-University Munich.
She studied medicine at the Georg-August University in Göttingen and the Technical University in Munich.
She had worked on her specialization in Dermatology and Allergology at the University Hospital of Munich (LMU) for two years and received her postdoctoral training as a Fellow of the German Research Foundation at the Basel Institute for Immunology.
Aktive Positionen von Annegret de Baey-Diepolder
Unternehmen | Position | Beginn |
---|---|---|
Seventure Partners SA
Seventure Partners SA Investment ManagersFinance Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris. | Private Equity Investor | 01.04.2017 |
Ehemalige bekannte Positionen von Annegret de Baey-Diepolder
Unternehmen | Position | Ende |
---|---|---|
Vivendy Therapeutics Ltd.
Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Direktor/Vorstandsmitglied | 10.03.2014 |
Gimv Life Sciences
Gimv Life Sciences Investment ManagersFinance Gimv Life Sciences (Gimv-LS) is the venture capital division of Belgium's Gimv NV (XB: GIMB), an investment firm founded in 1980. Based in Antwerp, Gimv-LS manages a variety of funds which focus on investing in European companies in the life sciences / biotech sector, including the Biotech Fonds Vlaanderen, which was established at the request of the Flemish Region to provide venture capital to existing and start-up medium and large-sized companies in the Flemish biotechnology sector. | Corporate Officer/Principal | 01.09.2011 |
TVM Capital GmbH
TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Private Equity Investor | 14.04.2010 |
Rigontec GmbH
Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Gründer | - |
Ausbildung von Annegret de Baey-Diepolder
Ludwig-Maximilians-Universität München | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
TVM Capital GmbH
TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Finance |
Vivendy Therapeutics Ltd.
Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Health Services |
Gimv Life Sciences
Gimv Life Sciences Investment ManagersFinance Gimv Life Sciences (Gimv-LS) is the venture capital division of Belgium's Gimv NV (XB: GIMB), an investment firm founded in 1980. Based in Antwerp, Gimv-LS manages a variety of funds which focus on investing in European companies in the life sciences / biotech sector, including the Biotech Fonds Vlaanderen, which was established at the request of the Flemish Region to provide venture capital to existing and start-up medium and large-sized companies in the Flemish biotechnology sector. | Finance |
Rigontec GmbH
Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Health Technology |
Seventure Partners SA
Seventure Partners SA Investment ManagersFinance Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris. | Finance |